Cancer- and Cancer Treatment–Associated Cognitive Change: An Update on the State of the Science

Ahles, Tim A.; Root, James C.; Ryan, Elizabeth

doi:10.1200/jco.2012.43.0116

Cited by 590 publications

(516 citation statements)

References 77 publications

Supporting

Mentioning

457

Contrasting

Unclassified

Order By: Relevance

“…Whereas this pattern is typically characteristic of advancing age [5], increases in the slowest frequency (delta) were associated with complaints even when controlling for subjects' chronological age. This observation is consistent with a hypothesis that models of aging may prove useful in conceptualizing cognitive complaints in this population [4]. Additionally, overall cognitive complaints were associated with temporoparietal and occipital decreases in relative beta power.…”

Section: Discussionsupporting

confidence: 89%

Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study

Hunter

Kwan²,

Ercoli³

et al. 2014

Psycho-Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study

Hunter

Kwan²,

Ercoli³

et al. 2014

Psycho-Oncology

View full text Add to dashboard Cite

“…Chemotherapy has been associated with short‐term and long‐term18, 53 cognitive decrements in many settings and populations, but the effects are not universal 37, 54. The results of the current study suggest that the majority of older survivors of breast cancer maintain high self‐reported cognitive function, but that chemotherapy (with or without hormonal treatment), which was received by the healthiest older survivors,23 can have adverse long‐term effects in a small number of survivors.…”

Section: Discussionmentioning

confidence: 99%

Long‐term trajectories of self‐reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

Mandelblatt

Clapp

Luta

et al. 2016

Cancer

Self Cite

138

View full text Add to dashboard Cite

BACKGROUNDThe number of survivors of breast cancer aged ≥65 years (“older”) is growing, but to the authors' knowledge, little is known regarding the cognitive outcomes of these individuals.METHODSA cohort of cognitively intact older survivors with nonmetastatic, invasive breast cancer was recruited from 78 sites from 2004 through 2011; approximately 83.7% of the survivors (1280 survivors) completed baseline assessments. Follow‐up data were collected at 6 months and annually for up to 7 years (median, 4.1 years). Cognitive function was self‐reported using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30); scores ranged from 0 to 100, with a higher score indicating better function. Group‐based trajectory modeling determined trajectories; women were assigned to a trajectory group based on the highest predicted probability of membership. Multinomial logistic regression evaluated the association between receipt of chemotherapy (with or without hormonal treatment) and trajectory group.RESULTSSurvivors were aged 65 to 91 years; approximately 41% received chemotherapy. There were 3 cognitive trajectories: “maintained high” (42.3% of survivors); “phase shift” (50.1% of survivors), with scores slightly below but parallel to maintained high; and “accelerated decline” (7.6% of survivors), with the lowest baseline scores and greatest decline (from 71.7 [standard deviation, 19.8] to 58.3 [standard deviation, 21.9]). The adjusted odds of being in the accelerated decline group (vs the maintained high group) were 2.1 times higher (95% confidence interval, 1.3‐3.5) for survivors who received chemotherapy (with or without hormonal therapy) versus those treated with hormonal therapy alone. Greater comorbidity and frailty also were found to be associated with accelerated decline.CONCLUSIONSTrajectory group analysis demonstrated that the majority of older survivors maintained good long‐term self‐reported cognitive function, and that only a small subset who were exposed to chemotherapy manifested accelerated cognitive decline. Future research is needed to determine factors that place some older survivors at risk of experiencing cognitive decline. Cancer 2016;122:3555–3563. © 2016 American Cancer Society

show abstract

“…1 However, important gaps remain in this area. One is the paucity of studies on patients with prostate cancer, the most common cancer in US men.…”

Section: Introductionmentioning

confidence: 99%

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison

Gonzalez

Jim

Booth-Jones

et al. 2015

JCO

171

156

View full text Add to dashboard Cite

Purpose Men receiving androgen-deprivation therapy (ADT) for prostate cancer may be at risk for cognitive impairment; however, evidence is mixed in the existing literature. Our study examined the impact of ADT on impaired cognitive performance and explored potential demographic and genetic predictors of impaired performance. Patients and Methods Patients with prostate cancer were assessed before or within 21 days of starting ADT (n = 58) and 6 and 12 months later. Age- and education-matched patients with prostate cancer treated with prostatectomy only (n = 84) and men without prostate cancer (n = 88) were assessed at similar intervals. Participants provided baseline blood samples for genotyping. Mean-level cognitive performance was compared using mixed models; cognitive impairment was compared using generalized estimating equations. Results ADT recipients demonstrated higher rates of impaired cognitive performance over time relative to all controls (P = .01). Groups did not differ at baseline (P > .05); however, ADT recipients were more likely to demonstrate impaired performance within 6 and 12 months (P for both comparisons < .05). Baseline age, cognitive reserve, depressive symptoms, fatigue, and hot flash interference did not moderate the impact of ADT on impaired cognitive performance (P for all comparisons ≥ .09). In exploratory genetic analyses, GNB3 single-nucleotide polymorphism rs1047776 was associated with increased rates of impaired performance over time in the ADT group (P < .001). Conclusion Men treated with ADT were more likely to demonstrate impaired cognitive performance within 6 months after starting ADT relative to matched controls and to continue to do so within 12 months after starting ADT. If confirmed, findings may have implications for patient education regarding the risks and benefits of ADT.

show abstract

Cancer- and Cancer Treatment–Associated Cognitive Change: An Update on the State of the Science

Cited by 590 publications

References 77 publications

Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study

Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study

Long‐term trajectories of self‐reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison

Contact Info

Product

Resources

About